<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230714063306&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vU e PJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=出版-2<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230714063306&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 14 日星期五 10:33:07 +0000</lastbuilddate><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>严重感染抗血栓治疗患者的管理：ESC血栓形成工作组、ESC动脉粥样硬化和血管生物学工作组以及国际血栓和止血学会联合临床共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>患有严重感染且已有抗血栓治疗指征（即抗血小板药物、抗凝药物或其组合）的患者需要凝血、感染性疾病和心脏病专家之间的综合临床咨询，因为脓毒症引起的凝血病经常发生。病毒病原体对全球公共卫生构成越来越大的威胁，特别是对于正在接受抗血栓治疗的患者来说，这些患者有很高的风险…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 13:ehad388.doi: 10.1093/eurheartj/ehad388. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">患有严重感染且已有抗血栓治疗指征（即抗血小板药物、抗凝药物或其组合）的患者需要凝血、感染性疾病和心脏病专家之间的综合临床咨询，因为脓毒症引起的凝血病经常发生。病毒病原体对全球公共卫生构成越来越大的威胁，特别是对于正在进行抗血栓治疗的患者来说，他们血栓复发的风险很高，并且对严重感染的易感性很高，从而导致发病率和死亡率增加。凝血功能障碍常常使严重感染复杂化，与死亡率高，临床医生有义务调整抗血栓药物类型和剂量，以避免出血，同时预防血栓并发症。本临床共识声明回顾了现有的最佳证据，为因严重细菌或病毒感染而住院的患者的治疗提供专家意见和声明-抗血栓治疗（单一或联合）的现有适应症，其中经常观察到脓毒症引起的凝血病。平衡这些患者的血栓形成和出血风险并使用疫苗预防感染（如果有）对于预防事件或改善结果至关重要；预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37439553</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad388>10.1093/eurheartj/ehad388</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439553</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>布鲁纳·吉甘特</dc:creator><dc:creator>杰罗德·H·利维</dc:creator><dc:creator>埃里克·范·戈尔普</dc:creator><dc:creator>亚历山德罗·巴托洛尼</dc:creator><dc:creator>玛丽·露丝·博查顿·皮亚拉</dc:creator><dc:creator>马格努斯·贝克</dc:creator><dc:creator>雨果十大美食</dc:creator><dc:creator>克里斯蒂娜·克里斯特森</dc:creator><dc:creator>何塞·路易斯·费雷罗</dc:creator><dc:creator>托比亚斯·盖斯勒</dc:creator><dc:creator>埃丝特·鲁特根斯</dc:creator><dc:creator>——萨姆·舒尔曼</dc:creator><dc:creator>罗伯特·F·斯托里</dc:creator><dc:creator>杰科·塔奇尔</dc:creator><dc:creator>杰玛·维拉胡尔</dc:creator><dc:creator>Patricia C Liaw更多</dc:creator><dc:creator>比安卡·罗卡</dc:creator><dc:date>2023-07-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>严重感染抗血栓治疗患者的管理：ESC血栓形成工作组、ESC动脉粥样硬化和血管生物学工作组以及国际血栓和止血学会联合临床共识声明</dc:title><dc:identifier>下午：37439553</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad388</dc:identifier></item><item><title> BNT162b2 和 mRNA-1273 疫苗接种对健康成人血管功能的影响：初步研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 13 日。doi：10.1161/CIRCRESAHA.122.322862。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37439257</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322862>10.1161/CIRCRESAHA.122.322862</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439257</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>科琳娜·塞文特</dc:creator><dc:creator>亚历克斯·马蒂亚斯</dc:creator><dc:creator>米娅·卡尔德隆</dc:creator><dc:creator>穆罕默德·埃内斯·埃罗尔</dc:creator><dc:creator>斯图尔特·奇普金</dc:creator><dc:creator>格温纳尔·拉耶克</dc:creator><dc:date>2023-07-13</dc:date><dc:source>流通研究</dc:source><dc:title>BNT162b2 和 mRNA-1273 疫苗接种对健康成人血管功能的影响：初步研究</dc:title><dc:identifier>下午：37439257</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322862</dc:identifier></item><item><title>双器官移植：心肾和心肝移植的适应症、评估和结果：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>虽然心脏移植是晚期心力衰竭患者的首选治疗方法，但同时存在的肾或肝功能障碍可能会对孤立心脏移植构成障碍。因此，对同步心肾移植和同步心肝移植有明确的指导是迫切需要的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 13 日。doi：10.1161/CIR.0000000000001155。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">虽然心脏移植是晚期心力衰竭患者的首选治疗方法，但同时存在的肾或肝功能障碍可能会对孤立心脏移植构成障碍。因此，对同步心肾移植和同步心肝移植有明确的指导迫切需要（3）为同时心肾移植和同时心肝移植的患者选择和移植后管理提供方法；（4）探索多器官移植的伦理学。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37439224</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001155>10.1161/CIR.0000000000001155</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439224</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——米歇尔·M·基特尔森</dc:creator><dc:creator>卡维塔·夏尔马</dc:creator><dc:creator>丹尼尔·布伦南</dc:creator><dc:creator>程星星</dc:creator><dc:creator>周雪儿</dc:creator><dc:creator>莫妮卡·科尔文</dc:creator><dc:creator>——亚当·D·德沃尔</dc:creator><dc:creator>香农·M·邓利</dc:creator><dc:creator>——梅格·弗雷泽</dc:creator><dc:creator>杰奎琳·加隆齐克·王</dc:creator><dc:creator>普拉泰提·哈赞尼</dc:creator><dc:creator>——凯文·M·科伦布拉特</dc:creator><dc:creator>范德T</dc:creator><dc:creator>美国心脏协会临床心脏病学委员会心力衰竭和移植委员会；心血管疾病肾脏委员会；心血管手术和麻醉委员会；心血管和中风护理委员会；先天性心脏病和年轻人心脏健康</dc:creator><dc:date>2023-07-13</dc:date><dc:source>循环</dc:source><dc:title>双器官移植：心肾和心肝移植的适应症、评估和结果：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37439224</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001155</dc:identifier></item><item><title> STREAM-2 中半剂量替奈普酶或初次经皮冠状动脉介入治疗老年 ST 段抬高型心肌梗死患者：一项随机、开放标签试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>结论：在这种早期出现的老年 STEMI 人群中，在药物侵入策略中将替奈普酶剂量减半与心电图变化相关，这些变化至少与直接 PCI 后的变化相当。两个治疗组中出现相似的临床疗效和血管造影终点半剂量替奈普酶的颅内出血风险高于直接 PCI。如果无法及时进行 PCI，这种药物侵入策略是一种合理的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 13 日。doi：10.1161/CIRCULATIONAHA.123.064521。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：ST 段抬高型心肌梗死 (STEMI) 指南建议，如果无法及时进行直接经皮冠状动脉介入治疗 (PCI)，则建议采用药物侵入性治疗。全剂量替奈普酶会增加老年患者颅内出血的风险。半剂量替奈普酶对于老年 STEMI 患者是否有效且安全尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：STREAM-2（心肌梗死后早期老年患者的策略性再灌注）是一项研究者发起的、开放标签、随机、多中心研究。患者年龄≥60岁，2个连续导联ST段抬高≥2mm，无法在 1 小时内接受直接 PCI 的患者，被随机分配 (2:1) 接受半剂量替奈普酶治疗，然后在随机分组后 6 至 24 小时进行冠状动脉造影和 PCI（如果需要），或接受直接 PCI。 主要关注的疗效终点是 ST 消退和 30 天的死亡、休克、心力衰竭或再梗塞综合情况。安全性评估包括中风和非颅内出血。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者被分配接受药物侵入性治疗 (n=401) 或直接 PCI (n=203)。从随机分组到替奈普酶或鞘管插入的中位时间分别为 10 分钟和 81 分钟。最后一次血管造影后，85.2% 的患者接受了药物侵入性治疗和 78.4% 接受直接 PCI 的患者 ST 段抬高的缓解率≥50%；他们的 ST 段偏差的残余中位总和分别为 4.5 毫米和 5.5 毫米。最后一次血管造影时心肌梗塞血流 3 级溶栓治疗为 ≈两组均为 87%。复合临床终点发生在接受药物侵入性治疗的患者中为 12.8% (51/400)，在接受直接 PCI 的患者中为 13.3% (27/203)（相对风险，0.96 [95% CI， 0.62-1.48]）。药物侵入组发生 6 例颅内出血（1.5%）：3 例违反方案（2 例过度抗凝，1 例高血压未控制）。初次 PCI 组未发生颅内出血。主要非颅内出血两组的比例均较低（&lt;1.5%）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在这种早期出现的老年 STEMI 人群中，在药物侵入策略中将替奈普酶剂量减半与心电图变化相关，这些变化至少与直接 PCI 后的变化相当。两个治疗组中出现相似的临床疗效和血管造影终点半剂量替奈普酶的颅内出血风险高于直接PCI。如果无法及时进行PCI，这种药物侵入性策略是一个合理的替代方案，前提是观察到纤溶禁忌症并避免过度抗凝。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT02777580。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37439219</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064521>10.1161/CIRCULATIONAHA.123.064521</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439219</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>弗兰斯·范德沃夫</dc:creator><dc:creator>阿森·D·里斯蒂奇</dc:creator><dc:creator>奥列格·V·阿韦尔科夫</dc:creator><dc:creator>亚历山德拉·阿里亚斯·门多萨</dc:creator><dc:creator>伊夫·兰伯特</dc:creator><dc:creator>何塞·F·克尔·萨莱瓦</dc:creator><dc:creator>巴勃罗·塞普尔韦达</dc:creator><dc:creator>费尔南多·罗塞尔-奥尔蒂斯</dc:creator><dc:creator>约翰·K·弗伦奇</dc:creator><dc:creator>Ljilja B 音乐</dc:creator><dc:creator>凯琳·范登伯格</dc:creator><dc:creator>克里斯·博加茨</dc:creator><dc:creator>辛西娅·M·韦斯特豪特</dc:creator><dc:creator>阿兰·佩吉斯</dc:creator><dc:creator>蒂埃里·达内斯</dc:creator><dc:creator>——凯文·R·贝尼</dc:creator><dc:creator>彼得·辛尼夫</dc:creator><dc:creator>——帕特里克·戈德斯坦</dc:creator><dc:creator>——罗伯特·C·威尔士</dc:creator><dc:creator>保罗·W·阿姆斯特朗</dc:creator><dc:creator>STREAM-2 调查员</dc:creator><dc:date>2023-07-13</dc:date><dc:source>循环</dc:source><dc:title>STREAM-2 中半剂量替奈普酶或初次经皮冠状动脉介入治疗老年 ST 段抬高型心肌梗死患者：一项随机、开放标签试验</dc:title><dc:identifier>下午：37439219</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064521</dc:identifier></item><item><title>生命早期累积的危险因素暴露</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):e19.doi: 10.1016/j.jacc.2023.04.055。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438013</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.055>10.1016/j.jacc.2023.04.055</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438013</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>生命早期累积的危险因素暴露</dc:title><dc:identifier>下午：37438013</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.055</dc:identifier></item><item><title>肥厚型心肌病合并心房颤动患者发生左心房血栓的风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):278-279.doi:10.1016/j.jacc.2023.05.021。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438012</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.021>10.1016/j.jacc.2023.05.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438012</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——丹尼尔·R·布尔扎克</dc:creator><dc:creator>Raghav R Julakanti更多</dc:creator><dc:creator>阿卜杜拉·卡拉·巴拉</dc:creator><dc:creator>克里斯托弗·斯科特</dc:creator><dc:creator>杰弗里·B·盖斯克</dc:creator><dc:creator>史蒂夫·R·奥曼</dc:creator><dc:creator>乌伊西勒·T·恩科莫</dc:creator><dc:creator>——伯纳德·J·格什</dc:creator><dc:creator>彼得·鼻子</dc:creator><dc:creator>康斯坦丁诺斯·西昂蒂斯</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>肥厚型心肌病合并心房颤动患者发生左心房血栓的风险</dc:title><dc:identifier>下午：37438012</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.021</dc:identifier></item><item><title>避免接受血管内主动脉弓修复术的患者发生中风：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>作为血管内主动脉弓修复的瓶颈，术后早期卒中仍然是高危患者的毁灭性并发症，也是开发最佳血管内技术和设备的关键问题。据报道，发生率从 0.0% 到 42.9% 不等，并且显着降低了术后早期卒中的发生率。受患者先前存在的主动脉粥样硬化严重程度的影响... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):265-277.doi:10.1016/j.jacc.2023.04.053。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">作为血管内主动脉弓修复的瓶颈，术后早期卒中仍然是高危患者的毁灭性并发症，也是开发最佳血管内技术和设备的关键问题。据报道，发生率从 0.0% 到 42.9% 不等，并且显着降低了术后早期卒中的发生率。受患者先前存在的主动脉粥样硬化负荷的严重程度、血管内装置释放的空气以及导致脑灌注不足的多种因素的影响。高风险患者和仔细的围手术期管理似乎在降低脑卒中发生率方面发挥着关键作用。具体术中预防方法仍然缺乏，但栓塞防护装置和二氧化碳或高容量盐水冲洗血管内装置似乎很有希望。详细的术前卒中风险分层和筛选最佳的血管内技术和主动脉弓治疗装置尚未满足临床需求。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438011</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.053>10.1016/j.jacc.2023.04.053</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438011</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>曹龙</dc:creator><dc:creator>张宏鹏</dc:creator><dc:creator>葛阳阳</dc:creator><dc:creator>卫国</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>避免接受血管内主动脉弓修复术的患者发生中风：JACC 本周评论主题</dc:title><dc:identifier>下午：37438011</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.053</dc:identifier></item><item><title>心血管医学中的消费者可穿戴健康和健身技术：JACC 最先进的评论</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>近年来，由于技术的进步，使用消费者可穿戴设备 (CWD) 来跟踪健康和健身的情况迅速扩大。普通大众现在有能力持续跟踪生命体征、运动量和高级健康指标。基本健康指标可能是直观的（例如峰值心率），更复杂的指标来自专有算法，设备制造商之间有所不同，并且历史上可能并不常见...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):245-264.doi:10.1016/j.jacc.2023.04.054。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">近年来，由于技术的进步，使用消费者可穿戴设备 (CWD) 来跟踪健康和健身的情况迅速扩大。普通大众现在有能力持续跟踪生命体征、运动量和高级健康指标。基本健康指标可能是直观的（例如峰值心率），更复杂的指标源自专有算法，设备制造商之间有所不同，并且历史上在临床实践中可能并不常见（例如峰值 V˙O <sub>2</sub> 、运动恢复分数）。扩展在个体患者层面收集的数据，仔细解释是必要的。在这篇综述中，我们批判性地分析了 CWD 提供的常见健康指标，描述了 CWD 解释中的常见陷阱，提供了解释异常结果的建议，介绍了 CWD 的实用性在运动处方方面，研究 CWD 使用和开发中的健康差异和不平等，并提出未来的研究和开发方向。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438010</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.054>10.1016/j.jacc.2023.04.054</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438010</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>布拉德利·J·佩特克</dc:creator><dc:creator>穆斯塔法·阿尔·阿鲁西</dc:creator><dc:creator>——纳撒尼尔·莫尔森</dc:creator><dc:creator>奥布里·J·格兰特</dc:creator><dc:creator>西里尔·贝松</dc:creator><dc:creator>J·萨瓦拉·古塞</dc:creator><dc:creator>梅根·M·沃斯菲</dc:creator><dc:creator>文森特·格雷莫</dc:creator><dc:creator>蒂莫西·丘吉尔</dc:creator><dc:creator>亚伦·L·巴吉什</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管医学中的消费者可穿戴健康和健身技术：JACC 最先进的评论</dc:title><dc:identifier>下午：37438010</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.054</dc:identifier></item><item><title> （左）穿好衣服！冠状动脉窦越来越冷了</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):242-244.doi:10.1016/j.jacc.2023.05.019。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438009</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.019>10.1016/j.jacc.2023.05.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438009</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·P·莫林</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>（左）穿好衣服！冠状动脉窦越来越冷了</dc:title><dc:identifier>下午：37438009</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.019</dc:identifier></item><item><title> ARVC 家庭筛查的精确方法</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):226-227.doi:10.1016/j.jacc.2023.05.020。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438008</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.020>10.1016/j.jacc.2023.05.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438008</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>保罗·A·海登赖希</dc:creator><dc:creator>弗朗索瓦·哈达德</dc:creator><dc:creator>维多利亚·N·帕里克</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>ARVC 家庭筛查的精确方法</dc:title><dc:identifier>下午：37438008</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.020</dc:identifier></item><item><title>心脏骤停中的社区志愿者急救计划：马已脱缰，是时候优化了</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):211-213.doi:10.1016/j.jacc.2023.05.018。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438007</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.018>10.1016/j.jacc.2023.05.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438007</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>珍妮特·E·布雷</dc:creator><dc:creator>克里斯托弗·M·史密斯</dc:creator><dc:creator>齐亚德·内梅</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心脏骤停中的社区志愿者急救计划：马已脱缰，是时候优化了</dc:title><dc:identifier>下午：37438007</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.018</dc:identifier></item><item><title>派遣志愿者应对院外心脏骤停</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>结论：与不激活系统相比，在 OHCA 病例中激活志愿者反应系统与旁观者心肺复苏、旁观者除颤和 30 天生存率较高相关。需要进行随机对照试验来充分确定志愿者反应者的因果效应系统。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):200-210.doi:10.1016/j.jacc.2023.05.017。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：用于派遣志愿者响应人员收集自动体外除颤器和/或在附近院外心脏骤停 (OHCA) 的情况下提供心肺复苏 (CPR) 的系统已得到广泛实施。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在调查与未激活系统相比，激活 OHCA 志愿者响应系统是否与较高的旁观者心肺复苏、旁观者除颤率和 30 天生存率相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是 ESCAPE-NET（欧洲心脏骤停网络：迈向预防、教育、新有效治疗）协作研究网络内的一项回顾性观察分析。包括 2015 年至 2019 年来自 5 个拥有志愿者响应系统的欧洲站点的 OHCA 病例在所有地点，紧急医疗通信中心的调度员均启动了系统，以应对疑似 OHCA。将暴露病例（系统激活）与非暴露病例（未激活系统）进行比较。计算旁观者结果的风险比 (RR)心肺复苏、旁观者除颤和逆概率治疗加权后的 30 天生存率。使用多重插补处理缺失数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共纳入了 9,553 例病例。其中 4,696 例激活了志愿者响应系统，4,857 例未激活。旁观者 CPR 的汇总 RR 为 1.30 (95% CI: 1.15-1.47)，旁观者 CPR 为 1.89 (95%)旁观者除颤的 CI：1.36-2.63），30 天生存的 CI：1.22（95% CI：1.07-1.39）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与不激活系统相比，在 OHCA 病例中激活志愿者反应系统与旁观者心肺复苏、旁观者除颤和 30 天生存率较高相关。需要进行随机对照试验来充分确定志愿者反应者的因果效应系统。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438006</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.017>10.1016/j.jacc.2023.05.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438006</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>马丁·琼森</dc:creator><dc:creator>埃莉诺·伯格伦德</dc:creator><dc:creator>恩里科·巴尔迪</dc:creator><dc:creator>玛丽亚·卢斯·卡普托</dc:creator><dc:creator>安吉洛·奥里奇奥</dc:creator><dc:creator>玛丽克·T·布洛姆</dc:creator><dc:creator>汉诺·谭</dc:creator><dc:creator>雷米·斯蒂格利斯</dc:creator><dc:creator>林恩·安德鲁斯</dc:creator><dc:creator>弗雷德里克·福克</dc:creator><dc:creator>雅各布·霍伦伯格</dc:creator><dc:creator>莱夫·斯文森</dc:creator><dc:creator>马蒂亚斯·林格</dc:creator><dc:creator>ESCAPE-NET 调查员</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>派遣志愿者应对院外心脏骤停</dc:title><dc:identifier>下午：37438006</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.017</dc:identifier></item><item><title>生物可吸收支架：隧道尽头还有光明吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):196-199.doi:10.1016/j.jacc.2023.05.023。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37438005</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.023>10.1016/j.jacc.2023.05.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438005</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——帕特里克·W·塞鲁伊斯</dc:creator><dc:creator>普鲁特维·C·雷瓦亚</dc:creator><dc:creator>大沼嘉信</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>生物可吸收支架：隧道尽头还有光明吗？</dc:title><dc:identifier>下午：37438005</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.023</dc:identifier></item><item><title>叶绿体蛋白质图谱揭示了生物合成途径的点状结构和空间组织</title><link/>https://pubmed.ncbi.nlm.nih.gov/37437571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>叶绿体是驱动全球碳循环的真核光合细胞器。尽管它们很重要，但我们对其蛋白质组成、功能和空间组织的了解仍然有限。在这里，我们使用荧光蛋白标记在模型藻类中确定了 1,034 个候选叶绿体蛋白的定位莱茵衣藻。定位提供了对特征较差的蛋白质功能的深入了解；识别核苷的新成分，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 6 日：S0092-8674(23)00676-1.doi: 10.1016/j.cell.2023.06.008.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">叶绿体是驱动全球碳循环的真核光合细胞器。尽管它们很重要，但我们对其蛋白质组成、功能和空间组织的了解仍然有限。在这里，我们使用荧光蛋白标记在模型藻类中确定了 1,034 个候选叶绿体蛋白的定位莱茵衣藻。这些定位提供了对特征较差的蛋白质功能的深入了解；识别了核仁、质体球和蛋白核的新成分；并揭示了针对多个区室的广泛蛋白质靶向。、胞质新月形结构以及叶绿体内酶的意外空间分布我们还使用机器学习来预测其他核编码衣藻蛋白的定位。这里开发的菌株和定位图谱将作为加速叶绿体结构和功能研究的资源。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37437571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37437571</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.008>10.1016/j.cell.2023.06.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37437571</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>王连勇</dc:creator><dc:creator>韦罗尼卡·帕特纳</dc:creator><dc:creator>凯利·范巴伦</dc:creator><dc:creator>谢一华</dc:creator><dc:creator>艾米丽·R·辛格</dc:creator><dc:creator>索菲亚·加夫里连科</dc:creator><dc:creator>——米歇尔·沃伦·威廉姆斯</dc:creator><dc:creator>临朐韩</dc:creator><dc:creator>——亨利·哈里根</dc:creator><dc:creator>林尼·D·哈茨</dc:creator><dc:creator>Vivian Chen更多</dc:creator><dc:creator>荣TNP吨</dc:creator><dc:creator>苏金</dc:creator><dc:creator>亨利·H·瑞</dc:creator><dc:creator>——马修·H·卡恩</dc:creator><dc:creator>——亚历山德拉·T·威尔逊</dc:creator><dc:creator>大西雅之</dc:creator><dc:creator>胡建平</dc:creator><dc:creator>丹尼·J·施内尔</dc:creator><dc:creator>克莱尔·D·麦克怀特</dc:creator><dc:creator>马丁·乔尼卡斯</dc:creator><dc:date>2023-07-12</dc:date><dc:source>细胞</dc:source><dc:title>叶绿体蛋白质图谱揭示了生物合成途径的点状结构和空间组织</dc:title><dc:identifier>下午：37437571</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.008</dc:identifier></item><item><title>工程 RNA 输出用于活细胞的测量和操作</title><link/>https://pubmed.ncbi.nlm.nih.gov/37437570/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>一种从活细胞中可编程导出 RNA 分子的系统将能够对细胞动力学进行非破坏性监测，并能够对能够将可执行 RNA 程序传递给其他细胞的细胞进行工程改造，并在保护性纳米颗粒内从哺乳动物细胞中分泌货物 RNA 分子。 RNA 条形码能够对细胞群进行无损监测... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Jul 10:S0092-8674(23)00689-X. doi: 10.1016/j.cell.2023.06.013. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">一种从活细胞中可编程导出 RNA 分子的系统将能够对细胞动力学进行非破坏性监测，并能够对能够将可执行 RNA 程序传递给其他细胞的细胞进行工程改造，并在保护性纳米颗粒内从哺乳动物细胞中分泌货物 RNA 分子。 RNA 条形码能够通过克隆分辨率对细胞群动态进行非破坏性监测。此外，通过将融合剂合并到纳米粒子中，我们证明了受体细胞中输出 mRNA 的递送、表达和功能活性。我们将这些系统称为 COURIER（受控输出和RNA 的摄取（用于询问、表达和调节）。RNA 的递送。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37437570/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37437570</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.013>10.1016/j.cell.2023.06.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37437570</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>菲利克斯·霍恩斯</dc:creator><dc:creator>乔·马丁内斯</dc:creator><dc:creator>范成成</dc:creator><dc:creator>梅赫纳兹·哈克</dc:creator><dc:creator>——詹姆斯·M·林顿</dc:creator><dc:creator>维多利亚·托宾</dc:creator><dc:creator>利亚·桑塔</dc:creator><dc:creator>艾莉娜·奥·马焦洛</dc:creator><dc:creator>——帕梅拉·J·比约克曼</dc:creator><dc:creator>卡洛斯·路易斯</dc:creator><dc:creator>——迈克尔·B·埃洛维茨</dc:creator><dc:date>2023-07-12</dc:date><dc:source>细胞</dc:source><dc:title>工程 RNA 输出用于活细胞的测量和操作</dc:title><dc:identifier>下午：37437570</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.013</dc:identifier></item><item><title>长 QT 综合征患者晕厥触发类型与后续危及生命事件的风险之间的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37436769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230714063306&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项研究中，LQTS 患者的触发特异性晕厥与后续 LTE 的不同风险和对 β 受体阻滞剂治疗的反应相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 12 日。doi：10.1001/jamacardio.2023.1951。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：晕厥是先天性长 QT 综合征 (LQTS) 患者后续危及生命事件 (LTE) 的最有力预测因子。不同的晕厥触发因素是否与后续 LTE 风险的差异相关尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估 LQT 1 至 3 型 (LQT1-3) 患者中肾上腺素能 (AD) 和非肾上腺素能 (non-AD) 触发的晕厥事件与后续 LTE 风险之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这项回顾性队列研究包括来自 5 个国际 LQTS 注册中心（纽约州罗彻斯特；明尼苏达州罗彻斯特的梅奥诊所；以色列、荷兰和日本）的数据。研究人群包括 2938 名经基因证实患有 LQTS 的患者。 LQT1、LQT2 或 LQT3 源于单一 LQTS 致病变异。患者于 1979 年 7 月至 2021 年 7 月期间入组。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：AD 和非 AD 触发引起的晕厥。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：主要终点是首次发生 LTE。使用多变量 Cox 回归来确定 AD 或非 AD 触发的晕厥与基因型后续 LTE 风险之间的关联。在服用β受体阻滞剂的患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 2938 patients were included (mean [SD] age at enrollment, 29 [7] years; 1645 [56%] female). In 1331 patients with LQT1, a first syncope occurred in 365 (27%) and was induced mostly with AD triggers (243 [67%]). Syncope preceded 43 subsequent LTEs (68%). Syncopal episodes associated with AD triggers were associated with the highest risk of subsequent LTE (hazard ratio [HR], 7.61; 95% CI, 4.18-14.20; P &lt; .001), whereas the risk associated with syncopal events due to non-AD triggers was statistically nonsignificant (HR, 1.50; 95% CI, 0.21-4.77; P = .97). In 1106 patients with LQT2, a first syncope occurred in 283 (26%) and was associated with AD and non-AD triggers in 106 (37%) and 177 (63%), respectively. Syncope preceded 55 LTEs (56%). Both AD- and non-AD-triggered syncope were associated with a greater than 3-fold increased risk of subsequent LTE (HR, 3.07; 95% CI, 1.66-5.67; P ≤ .001 and HR, 3.45, 95% CI, 1.96-6.06; P ≤ .001, respectively). In contrast, in 501 patients with LQT3, LTE was preceded by a syncopal episode in 7 (12%). In patients with LQT1 and LQT2, treatment with β-blockers following a syncopal event was associated with a significant reduction in the risk of subsequent LTEs. The rate of breakthrough events during treatment with β-blockers was significantly higher among those treated with selective agents vs nonselective agents. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION AND RELEVANCE: In this study, trigger-specific syncope in LQTS patients was associated with differential risk of subsequent LTE and response to β-blocker therapy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37436769/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37436769</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.1951>10.1001/jamacardio.2023.1951</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37436769</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Arwa Younis</dc:creator><dc:creator> J Martijn Bos</dc:creator><dc:creator> Wojciech Zareba</dc:creator><dc:creator> Mehmet K Aktas</dc:creator><dc:creator> Arthur AM Wilde</dc:creator><dc:creator> Chadi Tabaja</dc:creator><dc:creator> Christopher Bodurian</dc:creator><dc:creator> Kathryn E Tobert</dc:creator><dc:creator> Scott McNitt</dc:creator><dc:creator> Bronislava Polonsky</dc:creator><dc:creator> Wataru Shimizu</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Ilan Goldenberg</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Association Between Syncope Trigger Type and Risk of Subsequent Life-Threatening Events in Patients With Long QT Syndrome</dc:title><dc:identifier> pmid:37436769</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1951</dc:identifier></item><item><title> Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in the Population Without Clinical Heart Failure-Reply</title><link/> https://pubmed.ncbi.nlm.nih.gov/37436758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230714063306&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Jul 12. doi: 10.1001/jamacardio.2023.1965. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37436758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37436758</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.1965>10.1001/jamacardio.2023.1965</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37436758</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Mahmoud Al Rifai</dc:creator><dc:creator> Xiaoming Jia</dc:creator><dc:creator> Vijay Nambi</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in the Population Without Clinical Heart Failure-Reply</dc:title><dc:identifier> pmid:37436758</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1965</dc:identifier></item><item><title> Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in the Population Without Clinical Heart Failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37436731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230714063306&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Jul 12. doi: 10.1001/jamacardio.2023.1962. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37436731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37436731</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.1962>10.1001/jamacardio.2023.1962</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37436731</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Zhehao Dai</dc:creator><dc:creator> Sachiko Ohde</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in the Population Without Clinical Heart Failure</dc:title><dc:identifier> pmid:37436731</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1962</dc:identifier></item><item><title> &lt;em>;Streptococcus&lt;/em>; Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort</title><link/> https://pubmed.ncbi.nlm.nih.gov/37435755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230714063306&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study provides evidence of an association of a gut microbiota composition characterized by increased abundance of Streptococcus spp and other species commonly found in the oral cavity with coronary atherosclerosis and systemic inflammation markers. Further longitudinal and experimental studies are warranted to explore the potential implications of a bacterial component in atherogenesis. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Jul 12. doi: 10.1161/CIRCULATIONAHA.123.063914. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Gut microbiota have been implicated in atherosclerotic disease, but their relation with subclinical coronary atherosclerosis is unclear. This study aimed to identify associations between the gut microbiome and computed tomography-based measures of coronary atherosclerosis and to explore relevant clinical correlates. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a cross-sectional study of 8973 participants (50 to 65 years of age) without overt atherosclerotic disease from the population-based SCAPIS (Swedish Cardiopulmonary Bioimage Study). Coronary atherosclerosis was measured using coronary artery calcium score and coronary computed tomography angiography. Gut microbiota species abundance and functional potential were assessed with shotgun metagenomics sequencing of stool, and associations with coronary atherosclerosis were evaluated with multivariable regression models adjusted for cardiovascular risk factors. Associated species were evaluated for association with inflammatory markers, metabolites, and corresponding species in saliva. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The mean age of the study sample was 57.4 years, and 53.7% were female. Coronary artery calcification was detected in 40.3%, and 5.4% had at least 1 stenosis with >;50% occlusion. Sixty-four species were associated with coronary artery calcium score independent of cardiovascular risk factors, with the strongest associations observed for <i>Streptococcus anginosus</i> and <i>Streptococcus</i> <i>oralis</i> subsp <i>oralis</i> ( <i>P</i> &lt;1×10 <sup>-5</sup> ). Associations were largely similar across coronary computed tomography angiography-based measurements. Out of the 64 species, 19 species, including streptococci and other species commonly found in the oral cavity, were associated with high-sensitivity C-reactive protein plasma concentrations, and 16 with neutrophil counts. Gut microbial species that are commonly found in the oral cavity were negatively associated with plasma indole propionate and positively associated with plasma secondary bile acids and imidazole propionate. Five species, including 3 streptococci, correlated with the same species in saliva and were associated with worse dental health in the Malmö Offspring Dental Study. Microbial functional potential of dissimilatory nitrate reduction, anaerobic fatty acid β-oxidation, and amino acid degradation were associated with coronary artery calcium score. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study provides evidence of an association of a gut microbiota composition characterized by increased abundance of <i>Streptococcus</i> spp and other species commonly found in the oral cavity with coronary atherosclerosis and systemic inflammation markers. Further longitudinal and experimental studies are warranted to explore the potential implications of a bacterial component in atherogenesis.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37435755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37435755</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063914>10.1161/CIRCULATIONAHA.123.063914</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37435755</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Sergi Sayols-Baixeras</dc:creator><dc:creator> Koen F Dekkers</dc:creator><dc:creator> Gabriel Baldanzi</dc:creator><dc:creator> Daniel Jönsson</dc:creator><dc:creator> Ulf Hammar</dc:creator><dc:creator> Yi-Ting Lin</dc:creator><dc:creator> Shafqat Ahmad</dc:creator><dc:creator> Diem Nguyen</dc:creator><dc:creator> Georgios Varotsis</dc:creator><dc:creator> Sara Pita</dc:creator><dc:creator> Nynne Nielsen</dc:creator><dc:creator> Aron C Eklund</dc:creator><dc:creator> Jacob B Holm</dc:creator><dc:creator> H Bjørn Nielsen</dc:creator><dc:creator> Ulrika Ericson</dc:creator><dc:creator> Louise Brunkwall</dc:creator><dc:creator> Filip Ottosson</dc:creator><dc:creator> Anna Larsson</dc:creator><dc:creator> Dan Ericson</dc:creator><dc:creator> Björn Klinge</dc:creator><dc:creator> Peter M Nilsson</dc:creator><dc:creator> Andrei Malinovschi</dc:creator><dc:creator> Lars Lind</dc:creator><dc:creator> Göran Bergström</dc:creator><dc:creator> Johan Sundström</dc:creator><dc:creator> Johan Ärnlöv</dc:creator><dc:creator> Gunnar Engström</dc:creator><dc:creator> J Gustav Smith</dc:creator><dc:creator> Marju Orho-Melander</dc:creator><dc:creator> Tove Fall</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Circulation</dc:source><dc:title> &lt;em>;Streptococcus&lt;/em>; Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort</dc:title><dc:identifier> pmid:37435755</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.063914</dc:identifier></item><item><title> CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37435729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230714063306&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA, which provides a strong rationale for targeting this pathway. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Jul 12. doi: 10.1161/CIRCRESAHA.122.322330. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Giant cell arteritis (GCA) causes severe inflammation of the aorta and its branches and is characterized by intense effector T-cell infiltration. The roles that immune checkpoints play in the pathogenesis of GCA are still unclear. Our aim was to study the immune checkpoint interplay in GCA. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: First, we used VigiBase, the World Health Organization international pharmacovigilance database, to evaluate the relationship between GCA occurrence and immune checkpoint inhibitors treatments. We then further dissected the role of immune checkpoint inhibitors in the pathogenesis of GCA, using immunohistochemistry, immunofluorescence, transcriptomics, and flow cytometry on peripheral blood mononuclear cells and aortic tissues of GCA patients and appropriated controls. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Using VigiBase, we identified GCA as a significant immune-related adverse event associated with anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) but not anti-PD-1/PD-L1 treatment. We further dissected a critical role for the CTLA-4 pathway in GCA by identification of the dysregulation of CTLA-4-derived gene pathways and proteins in CD4 <sup>+</sup> T cells (and specifically regulatory T cells) present in blood and aorta of GCA patients versus controls. While regulatory T cells were less abundant and activated/suppressive in blood and aorta of GCA versus controls, they still specifically upregulated CTLA-4. Activated and proliferating CTLA-4 <sup>+</sup> Ki-67 <sup>+</sup> regulatory T cells from GCA were more sensitive to anti-CTLA-4 (ipilimumab)-mediated in vitro depletion versus controls. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA, which provides a strong rationale for targeting this pathway.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37435729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37435729</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.322330>10.1161/CIRCRESAHA.122.322330</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37435729</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Paul Régnier</dc:creator><dc:creator> Alexandre Le Joncour</dc:creator><dc:creator> Anna Maciejewski-Duval</dc:creator><dc:creator> Guillaume Darrasse-Jèze</dc:creator><dc:creator> Charles Dolladille</dc:creator><dc:creator> Wouter C Meijers</dc:creator><dc:creator> Lisa Bastarache</dc:creator><dc:creator> Pierre Fouret</dc:creator><dc:creator> Patrick Bruneval</dc:creator><dc:creator> Floriane Arbaretaz</dc:creator><dc:creator> Célia Sayetta</dc:creator><dc:creator> Ana Márquez</dc:creator><dc:creator> Michelle Rosenzwajg</dc:creator><dc:creator> David Klatzmann</dc:creator><dc:creator> Patrice Cacoub</dc:creator><dc:creator> Javid J Moslehi</dc:creator><dc:creator> Joe-Elie Salem</dc:creator><dc:creator> David Saadoun</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Circulation research</dc:source><dc:title> CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis</dc:title><dc:identifier> pmid:37435729</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322330</dc:identifier></item><item><title> Residual environmental risk in patients with cardiovascular disease: an overlooked paradigm</title><link/> https://pubmed.ncbi.nlm.nih.gov/37431798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230714063306&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 11:ehad412. doi: 10.1093/eurheartj/ehad412. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37431798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230714063306&v=2.17.9.post6+86293ac">37431798</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad412>10.1093/eurheartj/ehad412</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37431798</guid><pubDate> Tue, 11 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Sadeer Al-Kindi</dc:creator><dc:creator> Francesco Paneni</dc:creator><dc:creator> Robert D Brook</dc:creator><dc:creator> Sanjay Rajagopalan</dc:creator><dc:date> 2023-07-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Residual environmental risk in patients with cardiovascular disease: an overlooked paradigm</dc:title><dc:identifier> pmid:37431798</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad412</dc:identifier></item></channel></rss>